Anavex Life Sciences Corp(12X1)

Description: Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

---

Keywords: Pain Alzheimer's Disease Parkinson's Disease Rare Diseases Dementia Schizophrenia Depression Stroke Pancreatic Cancer Treatment Of Alzheimer's Disease Central Nervous System Disease Treatment Of Depression Learning Disabilities Fragile X Syndrome Antisense Therapy Rett Syndrome Frontotemporal Dementia Infantile Spasms Angelman Syndrome Treatment Of Central Nervous System Diseases

---

Home Page: www.anavex.com

630 5th Avenue
New York, NY 10111
United States
Phone: 844 689 3939

---

Officers

Exchange: F

Country: DE : Germany

Currency: Euro (€)